Berliner Boersenzeitung - Tests of HIV vaccine using mRNA technology have begun

EUR -
AED 4.028428
AFN 75.546833
ALL 98.755134
AMD 426.692562
ANG 1.987
AOA 1012.322544
ARS 1065.285355
AUD 1.617248
AWG 1.974193
AZN 1.862784
BAM 1.955308
BBD 2.226039
BDT 131.746827
BGN 1.955093
BHD 0.413456
BIF 3198.842463
BMD 1.096774
BND 1.431124
BOB 7.618082
BRL 5.984328
BSD 1.102522
BTN 92.511706
BWP 14.583328
BYN 3.607992
BYR 21496.767259
BZD 2.22224
CAD 1.491075
CDF 3148.837727
CHF 0.941174
CLF 0.036741
CLP 1013.802612
CNY 7.69771
CNH 7.7573
COP 4568.304333
CRC 571.892502
CUC 1.096774
CUP 29.064507
CVE 110.237243
CZK 25.348624
DJF 196.320568
DKK 7.456537
DOP 66.307536
DZD 145.770903
EGP 53.083633
ERN 16.451608
ETB 131.898806
FJD 2.3948
FKP 0.835258
GBP 0.838428
GEL 3.00532
GGP 0.835258
GHS 17.441608
GIP 0.835258
GMD 75.676748
GNF 9519.340843
GTQ 8.530852
GYD 230.651923
HKD 8.516614
HNL 27.414097
HRK 7.456977
HTG 145.372012
HUF 401.562921
IDR 17249.181533
ILS 4.144593
IMP 0.835258
INR 92.093357
IQD 1444.236351
IRR 46179.662415
ISK 148.908906
JEP 0.835258
JMD 174.206136
JOD 0.777175
JPY 162.737657
KES 141.484176
KGS 92.895697
KHR 4475.138408
KMF 492.396655
KPW 987.095834
KRW 1477.6064
KWD 0.336018
KYD 0.918769
KZT 532.445934
LAK 24344.870126
LBP 98727.541072
LKR 323.79847
LRD 212.791942
LSL 19.26105
LTL 3.238488
LVL 0.663427
LYD 5.257676
MAD 10.783785
MDL 19.34313
MGA 5049.728512
MKD 61.524374
MMK 3562.278649
MNT 3726.837458
MOP 8.81638
MRU 43.650392
MUR 51.087883
MVR 16.835472
MWK 1911.718642
MXN 21.112351
MYR 4.699634
MZN 70.067894
NAD 19.26105
NGN 1776.773172
NIO 40.572928
NOK 11.663747
NPR 148.026151
NZD 1.786431
OMR 0.422278
PAB 1.102522
PEN 4.106966
PGK 4.391235
PHP 62.337344
PKR 305.939566
PLN 4.32352
PYG 8593.83613
QAR 4.019788
RON 4.977483
RSD 117.010434
RUB 105.396586
RWF 1493.72389
SAR 4.119447
SBD 9.079876
SCR 14.938418
SDG 659.707888
SEK 11.369201
SGD 1.430248
SHP 0.835258
SLE 25.058324
SLL 22998.793393
SOS 630.04136
SRD 34.224538
STD 22701.004105
SVC 9.646571
SYP 2755.677106
SZL 19.253152
THB 36.664058
TJS 11.7423
TMT 3.849676
TND 3.372551
TOP 2.568755
TRY 37.570759
TTD 7.477117
TWD 35.300213
TZS 2988.70875
UAH 45.389271
UGX 4042.982004
USD 1.096774
UYU 46.111753
UZS 14046.463195
VEF 3973120.852889
VES 40.568947
VND 27254.829918
VUV 130.211194
WST 3.068184
XAF 655.791876
XAG 0.034354
XAU 0.000414
XCD 2.964086
XDR 0.819894
XOF 655.791876
XPF 119.331742
YER 274.526351
ZAR 19.12421
ZMK 9872.283811
ZMW 29.022692
ZWL 353.160729
  • CMSC

    -0.0400

    24.7

    -0.16%

  • SCS

    0.3500

    12.97

    +2.7%

  • RYCEF

    0.0000

    6.98

    0%

  • JRI

    -0.0200

    13.28

    -0.15%

  • RIO

    -0.1300

    69.7

    -0.19%

  • CMSD

    -0.0770

    24.813

    -0.31%

  • RBGPF

    58.9400

    58.94

    +100%

  • BCC

    0.6100

    138.9

    +0.44%

  • GSK

    0.4500

    38.82

    +1.16%

  • NGG

    -0.4700

    66.5

    -0.71%

  • AZN

    -0.4600

    77.47

    -0.59%

  • VOD

    -0.0300

    9.66

    -0.31%

  • BTI

    0.1800

    35.29

    +0.51%

  • BP

    0.4200

    32.88

    +1.28%

  • RELX

    -0.3200

    46.29

    -0.69%

  • BCE

    -0.1300

    33.71

    -0.39%

Tests of HIV vaccine using mRNA technology have begun
Tests of HIV vaccine using mRNA technology have begun

Tests of HIV vaccine using mRNA technology have begun

Testing in humans of an HIV vaccine that uses messenger RNA technology has begun, the biotech firm Moderna and the International AIDS Vaccine Initiative said Thursday.

Text size:

This Phase 1 trial is being carried out in the United States among 56 healthy adults who are HIV negative.

Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year.

But hopes have been stirred with the success of mRNA technology, which allowed for the development of Covid-19 vaccines in record time, including one from Moderna.

The goal of the vaccine now being tested is to stimulate production of a kind of antibody called "broadly neutralizing antibodies," or bnAbs, which can act against the many variants of HIV that are circulating today.

The vaccine is supposed to teach B lymphocytes, which are part of the immune system, to generate these antibodies.

In this trial, participants are injected with an immunogen -- a substance that can trigger an immune response -- and then a booster immunogen later.

These substances will be delivered with mRNA technology.

"The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process," Moderna and the IAVI, a research organization, said in a statement.

"Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen," said David Diemert, a lead investigator at one of the four sites where the trial is being carried out, George Washington University in the US capital.

The immunogens used in this trial were developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the US National Institute of Allergy and Infectious Diseases and Moderna.

A first trial last year tested the first immunogen but without employing mRNA technology. It showed that the desired immune response was triggered in dozens of people taking part in the research.

The next step was to bring in Moderna with its new mRNA technique.

"Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing," the Moderna-IAVI statement said.

"The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," said Mark Feinberg, the CEO of IAVI.

(L.Kaufmann--BBZ)